Literature DB >> 31741913

Artificial Intelligence/Machine Learning in Diabetes Care.

Rajiv Singla1, Ankush Singla2, Yashdeep Gupta3, Sanjay Kalra4.   

Abstract

Artificial intelligence/Machine learning (AI/ML) is transforming all spheres of our life, including the healthcare system. Application of AI/ML has a potential to vastly enhance the reach of diabetes care thereby making it more efficient. The huge burden of diabetes cases in India represents a unique set of problems, and provides us with a unique opportunity in terms of potential availability of data. Harnessing this data using electronic medical records, by all physicians, can put India at the forefront of research in this area. Application of AI/ML would provide insights to our problems as well as may help us to devise tailor-made solutions for the same. Copyright:
© 2019 Indian Journal of Endocrinology and Metabolism.

Entities:  

Keywords:  Artificial intelligence; diabetes care; machine learning

Year:  2019        PMID: 31741913      PMCID: PMC6844177          DOI: 10.4103/ijem.IJEM_228_19

Source DB:  PubMed          Journal:  Indian J Endocrinol Metab        ISSN: 2230-9500


Artificial intelligence (AI) is a broad term defined as the theory and development of virtual systems which are able to perform tasks normally by utilizing human intelligence such as visual perception, speech recognition, decision-making, and translation between languages.[1] It can be as simple as rule-based or driven by complex statistical methods. Machine learning is a subset of artificial intelligence (AI) that provides systems the ability to automatically learn and improve from experience without being explicitly programed.[12] Machine learning can be supervised, unsupervised, semi-supervised, or reinforcement based. Through deep learning machine tries to emulate human intelligence by simulating structure of human brain using recurrent neural networks. AI/ML tools are being extensively used in all scientific fields and are responsible for revolutionizing businesses throughout the world. Healthcare systems, on the other hand, have been very slow in adopting these advancements and are lagging far behind in this arena. AI/ML can be useful in the management of chronic diseases, namely, diabetes. In fact, ML/AI is already being used to predict risk of diabetes based on genomic data, diagnosis of diabetes based on EHR data, to predict risk of complications such as nephropathy and retinopathy, and also in diagnosis of diabetic retinopathy [Table 1].[3] There is a paucity of India specific data on all these aspects of AI in the published literature. Google AI research unit in collaboration with few Indian ophthalmology centers has already made great advances in the field of automated diagnosis and grading of diabetic retinopathy based on fundus photographs.[4] Adoption of these technologies can significantly increase detection and early treatment of diabetic complications.[4]
Table 1

Aspects of diabetes care using AI/ML

AreaDescription
Prediction of diabetesBased on genetic as well as clinical data, algorithms have been used to ascertain risk of occurrence of diabetes. Based on electronic health record data, certain algorithms can alert physicians towards possibility of diagnosis of diabetes being missed
Glycemic controlLargely pertains to artificial pancreas system. A large number of studies using different AI approaches have tried to automate insulin infusion rates based on continuous glucose monitoring (CGM) data and also to suggest insulin bolus dose
Prediction of glycemic eventsPrediction of impending hypoglycemia or hyperglycemia can be predicted based on CGM data. This approach is already in commercial use
Prediction of complicationsPrediction of risk of retinopathy, nephropathy, neuropathy or cardiovascular event by using baseline clinical and biochemical data
Diagnosis of complicationsAI/ML approach is revolutionizing detection of retinopathy in clinics of diabetologists by directly recognizing and classifying stages based on images obtained by fundus cameras
Aspects of diabetes care using AI/ML However, one area of diabetes care, that has seen very few attempts, is management strategies for diabetes. In type 1 diabetes we are witnessing the advancement of closed-loop insulin delivery system with inbuilt AI/ML algorithms to predict both hypoglycemic and hyperglycemic excursions.[5] These systems are still in infancy and yet to show an impact on long-term outcomes and quality of life. Treating type 2 diabetes is even more complicated than type 1 diabetes as there are multiple treatment options that are to be added sequentially and incrementally. Moreover, the choice of medication and its dosage also depends on a lot of individual factors such as BMI, underlying beta-cell function, and insulin resistance among others. There are excellent reviews on compiling studies that have used AI/ML approach in diabetes.

TYPE 2 DIABETES MANAGEMENT

AI/ML application would be even more useful in a country like India where the prevalence of diabetes is estimated at 8–10% with a slightly lower burden on rural areas as compared to urban areas.[6] However, in CARRS study, prevalence of diabetes in the city of Delhi has been determined at ~27% and it has been found that 46% or more population has prediabetes.[7] Similar prevalence has been found in three other metropolitan cities.[7] In another study, authors reported the highest incidence of diabetes in age group of 30–34 years.[8] Such an early and extensive occurrence of diabetes would be a huge burden on the healthcare system. Lack of resources, specially trained doctors, are a roadblock for health allover. The application of AI/ML in diabetes can help in plugging this huge gap. Uniformity of care (or minimum standard care) is another issue witnessed in India. As large number of cases are being handled by primary health care physicians and due to lack of any audit of these practices, average HbA1c of people with diabetes in India stays around 9%.[9] This predicts the potentially ever-increasing burden of complications resulting from poor diabetes control and also presents an opportunity to make things better with the help of AI/ML approach. An excellent effort by a group from the center for chronic disease control (CCDC) and AIIMS, implemented a decision support system on a mobile platform to help primary care physicians in making better choices for selecting diabetes management strategy.[1011] However, the intervention failed to show any improvement in glycemic control.[12] There can be few explanations for the same. First, there were logistic restrictions that were applicable for this study for example, only two drugs, viz, metformin and sulfonylureas were made available for titration; Second, drugs were only modified based on fasting blood glucose, postmeal blood glucose values, and HbA1c values. Inclusion of factors such as adherence to diet and exercise, compliance to medications might have increased practical utility of the intervention. Published literature on studies trying to optimize/automate therapy using machine learning algorithms at the patient level, on their routine visit is scant at the global level and is nonexistent at the national level. At the global level, there are few studies from China and western world.[131415] Studies on type 2 diabetes management strategies have been summarized in Table 2.
Table 2

Summary of studies using AI/ML in diabetes management

Authors, Year of publicationInstituteAimData SourceAI/ML approachResult
Jing Mei et al.[13] 2017, ChinaIBM Research ChinaTo provide personalized hypoglycemic medication prediction for diabetic patients21,796 patients from an EHR repository of a level 2 city in ChinaHierarchical recurrent neural network (HRNN)Successful use of HRNN but no clinical benefits elaborated.
Aileen P. Wright et al.[14] 2014, USAYale School of Medicine, New Haven, CT, United StatesIdentifying temporal relation- ships between medications and accurately predicting the next medication likely to be prescribed for a patientInpatient claims data from insuranceConstrained Sequential Pattern Discovery using Equivalence classesAuthors were able to predict the medication prescribed for 90.0% of patients when making predictions by drug class, and for 64.1% when making predictions at the generic drug level with three attempts
Adem Karahoca et al.[15] 2012. TurkeyBahçeßsehir University, TurkeyTo manage the drug dosage planning process for three anitdiabetes drugs namely Metformin, Gliclazide and PioglitazonesData set of T2DM patients were collected from Sinop State Hospital in Turkey.Diabetic data set had 142 diabetes assays from 45 T2DM patientsIndexing High Dimensional Model Representation (HDMR)Indexing HDMR method worked well in modeling drug dosages
Summary of studies using AI/ML in diabetes management A few caveats in these studies need to be noted while planning further research. First, these studies use data generated by multiple practitioners in routine diabetes care. While this may be the best way to get big data for analysis, it would not lead to an improvement in the standards of care. Moreover, at its best, system created from this data would match the outcomes of current practices. Second, due to multiple sources of data, noise level is likely to be very high making it difficult to delineate the most efficient path forward. Third, unless data has records of adherence to lifestyle measures (diet and exercise) and of compliance towards medication, the real-world utility of this AI/ML approach would be limited. Selecting specialist practices with glycemic control better than average would be the first step towards overcoming these problems. Careful prospective data collection by these practices should include records of compliance levels. Using supervised machine learning initially and gradually switching over to unsupervised machine learning would make this data relevant in the real world.

TYPE 1 DIABETES MANAGEMENT

There is a huge amount of literature on AI/ML approach being used in type 1 diabetes. There are algorithms that have been used to detect composition of food based on images of food thereby helping in carb counting.[16] Prediction of future blood glucose values and anticipating impending hypoglycemic or hyperglycemic event has been the focus of research in numerous publications.[17] Major work is also being done on developing bolus calculators to automate the process of calculating premeal insulin dose prediction.[18] From the perspective of the applicability of these approaches in India, there are two major lacunae. Firstly, most of this research is carried out among people using the insulin pumps and CGMs. As use of these modalities in India is limited due to economic issues, usability of this research in India is also limited. Secondly, different researchers have focused on individual areas of type 1 diabetes management and there is still no single application/technology available that can solve management of type 1 diabetes including carbohydrate counting, calculating insulin-carbohydrate ratios, and also predicting insulin dose for each meal for each patient, especially on multiple subcutaneous daily injections.

LIMITATIONS AND THE WAY FORWARD

AI/ML is as good as the data used to generate this intelligence. Our country is sometimes called as “country with no records”, however, this may not be exactly true but it does underline the general scenario of lack of record-keeping as an essential part of medical practice in India. A huge burden of disease can be transformed into an opportunity, if entire data is harnessed in a usable form and AI/ML is used to generate insights and solutions specific to our population. A concerted and collective effort is needed by the government and large associations, like, endocrine society of India to initiate data collections and research.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  14 in total

1.  Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs.

Authors:  Varun Gulshan; Lily Peng; Marc Coram; Martin C Stumpe; Derek Wu; Arunachalam Narayanaswamy; Subhashini Venugopalan; Kasumi Widner; Tom Madams; Jorge Cuadros; Ramasamy Kim; Rajiv Raman; Philip C Nelson; Jessica L Mega; Dale R Webster
Journal:  JAMA       Date:  2016-12-13       Impact factor: 56.272

2.  The use of sequential pattern mining to predict next prescribed medications.

Authors:  Aileen P Wright; Adam T Wright; Allison B McCoy; Dean F Sittig
Journal:  J Biomed Inform       Date:  2014-09-16       Impact factor: 6.317

3.  Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System.

Authors:  Laurel H Messer; Gregory P Forlenza; Jennifer L Sherr; R Paul Wadwa; Bruce A Buckingham; Stuart A Weinzimer; David M Maahs; Robert H Slover
Journal:  Diabetes Care       Date:  2018-02-14       Impact factor: 19.112

4.  Current glycemic status and diabetes related complications among type 2 diabetes patients in India: data from the A1chieve study.

Authors:  Viswanathan Mohan; Siddharth Shah; Banshi Saboo
Journal:  J Assoc Physicians India       Date:  2013-01

5.  Computer vision-based carbohydrate estimation for type 1 patients with diabetes using smartphones.

Authors:  Marios Anthimopoulos; Joachim Dehais; Sergey Shevchik; Botwey H Ransford; David Duke; Peter Diem; Stavroula Mougiakakou
Journal:  J Diabetes Sci Technol       Date:  2015-04-16

Review 6.  Machine Learning and Data Mining Methods in Diabetes Research.

Authors:  Ioannis Kavakiotis; Olga Tsave; Athanasios Salifoglou; Nicos Maglaveras; Ioannis Vlahavas; Ioanna Chouvarda
Journal:  Comput Struct Biotechnol J       Date:  2017-01-08       Impact factor: 7.271

7.  Temporal Change in Profile of Association between Diabetes, Obesity, and Age of Onset in Urban India: A Brief Report and Review of Literature.

Authors:  Rajiv Singla; Arpan Garg; Sweta Singla; Yashdeep Gupta
Journal:  Indian J Endocrinol Metab       Date:  2018 May-Jun

Review 8.  Data-Driven Blood Glucose Pattern Classification and Anomalies Detection: Machine-Learning Applications in Type 1 Diabetes.

Authors:  Ashenafi Zebene Woldaregay; Eirik Årsand; Taxiarchis Botsis; David Albers; Lena Mamykina; Gunnar Hartvigsen
Journal:  J Med Internet Res       Date:  2019-05-01       Impact factor: 5.428

9.  Current status of management, control, complications and psychosocial aspects of patients with diabetes in India: Results from the DiabCare India 2011 Study.

Authors:  Viswanathan Mohan; Siddharth N Shah; Shashank R Joshi; V Seshiah; Binode Kumar Sahay; Samar Banerjee; Subhash Kumar Wangnoo; Ajay Kumar; Sanjay Kalra; A G Unnikrishnan; Surendra Kumar Sharma; P V Rao; Shahid Akhtar; Raman V Shetty; Ashok Kumar Das
Journal:  Indian J Endocrinol Metab       Date:  2014-05

10.  Development of mWellcare: an mHealth intervention for integrated management of hypertension and diabetes in low-resource settings.

Authors:  Devraj Jindal; Priti Gupta; Dilip Jha; Vamadevan S Ajay; Shifalika Goenka; Pramod Jacob; Kriti Mehrotra; Pablo Perel; Jonathan Nyong; Ambuj Roy; Nikhil Tandon; Dorairaj Prabhakaran; Vikram Patel
Journal:  Glob Health Action       Date:  2018       Impact factor: 2.640

View more
  4 in total

Review 1.  Artificial intelligence perspective in the future of endocrine diseases.

Authors:  Mandana Hasanzad; Bagher Larijani; Hamid Reza Aghaei Meybodi; Negar Sarhangi
Journal:  J Diabetes Metab Disord       Date:  2022-01-11

2.  Developing Clinical Decision Support System using Machine Learning Methods for Type 2 Diabetes Drug Management.

Authors:  Rajiv Singla; Shivam Aggarwal; Jatin Bindra; Arpan Garg; Ankush Singla
Journal:  Indian J Endocrinol Metab       Date:  2022-04-27

3.  The Need for Ethnoracial Equity in Artificial Intelligence for Diabetes Management: Review and Recommendations.

Authors:  Quynh Pham; Anissa Gamble; Jason Hearn; Joseph A Cafazzo
Journal:  J Med Internet Res       Date:  2021-02-10       Impact factor: 5.428

4.  Improving Outcomes Through Personalized Recommendations in a Remote Diabetes Monitoring Program: Observational Study.

Authors:  Sowmya Kamath; Karthik Kappaganthu; Stefanie Painter; Anmol Madan
Journal:  JMIR Form Res       Date:  2022-03-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.